Zivo Bioscience, Inc. Common Stock
ZIVO
ZIVO was delisted on the 24th of November, 2023.
12 hedge funds and large institutions have $3.49M invested in Zivo Bioscience, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
167% more capital invested
Capital invested by funds: $1.31M → $3.49M (+$2.18M)
8% less funds holding
Funds holding: 13 → 12 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.8K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$477 |
| 4 |
JP Morgan Chase
New York
|
+$289 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$30.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$10.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.62K |
| 4 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$293 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$86 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $2.48M | +$2.9M | +170,645 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $660K | -$10.9K | -639 | -1% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $282K | +$19.8K | +1,165 | +6% |
|
4
Wells Fargo
San Francisco,
California
| $27.4K | – | – | – |
|
|
VCA
5
Verdence Capital Advisors
Hunt Valley,
Maryland
| $24.2K | – | – | – |
|
|
6
BlackRock
New York
| $12.2K | -$30.1K | -1,766 | -68% |
|
|
BCWM
7
Bartlett & Co Wealth Management
Cincinnati,
Ohio
| $2.42K | – | – | – |
|
|
BC
8
Bartlett & Co
Cincinnati,
Ohio
| $2K | – | – | – |
|
9
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $1.52K | – | – | – |
|
|
10
JP Morgan Chase
New York
| $242 | +$289 | +17 | New |
|
|
BCM
11
Bourgeon Capital Management
Darien,
Connecticut
| $76 | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$2.62K | -142 | Closed |
|
|
BAM
13
Belpointe Asset Management
Reno,
Nevada
| – | -$293 | -16 | Closed |
|
|
14
Bank of America
Charlotte,
North Carolina
| – | -$86 | -5 | Closed |
|
|
15
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$477 | +28 | New |
|
ZIVO Hedge Fund Activity: Q2 2023 in Review
12 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Zivo Bioscience, Inc. Common Stock (ZIVO) for Q2 2023, worth a combined $3.49M — up 167% from $1.31M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ZIVO and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.9M. The largest seller was BlackRock, cutting an estimated $30.1K.
- 12 institutional investors held Zivo Bioscience, Inc. Common Stock (ZIVO) as of Q2 2023, down from 13 in Q1 2023.
- Funds reported $3.49M of Zivo Bioscience, Inc. Common Stock stock for Q2 2023, up 167% quarter-over-quarter.
- 3 funds opened new Zivo Bioscience, Inc. Common Stock positions in Q2 2023 and 4 closed out, a net change of -1 holder.
- The largest Zivo Bioscience, Inc. Common Stock buyer in Q2 2023 was Armistice Capital, an estimated $2.9M added.
- The largest Zivo Bioscience, Inc. Common Stock seller in Q2 2023 was BlackRock, an estimated $30.1K sold.
Based on aggregated 13F filings for Q2 2023.